- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: CD11a.
Displaying page 1 of 1.
EudraCT Number: 2020-000517-33 | Sponsor Protocol Number: RP-L201-0318 | Start Date*: 2020-07-14 | |||||||||||
Sponsor Name:Rocket Pharmaceuticals, Inc. | |||||||||||||
Full Title: Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I):A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Len... | |||||||||||||
Medical condition: Leukocyte Adhesion Deficiency-I (LAD-I) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002680-26 | Sponsor Protocol Number: RP-L201-0218 | Start Date*: 2018-11-27 | |||||||||||
Sponsor Name:Rocket Pharmaceuticals, Inc. | |||||||||||||
Full Title: Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Lenti... | |||||||||||||
Medical condition: Leukocyte Adhesion Deficiency-I (LAD-I) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003833-25 | Sponsor Protocol Number: EFACLE2008 | Start Date*: 2009-02-05 | |||||||||||||||||||||
Sponsor Name:Universitätskrankenhaus Schleswig-Holstein | |||||||||||||||||||||||
Full Title: Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study | |||||||||||||||||||||||
Medical condition: Cutaneous lupus erythematosus (discoid LE or subacute cutaneous LE) or systemic lupus erythematosus with cutaneous DLE or SCLE lesions without major organ involvment. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006644-19 | Sponsor Protocol Number: CRISTAL | Start Date*: 2009-01-29 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA | |||||||||||||
Full Title: Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir base... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011662-28 | Sponsor Protocol Number: ABRACADABRA | Start Date*: 2009-11-26 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA | |||||||||||||
Full Title: Exploratory study on inflammatory immune response related to endothelial dysfunction in HIV-infected na�ve patients treated with abacavir compared to tenofovir-based regimens. | |||||||||||||
Medical condition: HIV INFECTION | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000709-10 | Sponsor Protocol Number: UKM12_0026 | Start Date*: 2014-12-19 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000497-30 | Sponsor Protocol Number: FIS-VED-2017-01 | Start Date*: 2018-05-28 | |||||||||||
Sponsor Name:Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI) | |||||||||||||
Full Title: Phase II clinical trial to evaluate the safety and efficacy of Vedolizumab combined with antiretroviral treatment to achieve functional healing in people infected with HIV-1 without previous antire... | |||||||||||||
Medical condition: Adult patients infected with HIV and without previous antiretroviral treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002714-23 | Sponsor Protocol Number: LLC1114 | Start Date*: 2015-01-07 | |||||||||||
Sponsor Name:Fondazione G.I.M.EM.A. Onlus Gruppo Italiano Malattie Ematologiche dell'Adulto | |||||||||||||
Full Title: A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL). | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
